MIMOSA: Morphine in Moderate Obstructive Sleep Apnoea

  • Research type

    Research Study

  • Full title

    The effect of acute intravenous (iv) morphine administration on Sleep Disordered Breathing (SDB) in patients with moderate Obstructive Sleep Apnoea (OSA): A paired design trial

  • IRAS ID

    148632

  • Contact name

    Martina Mason

  • Contact email

    martina.mason@papworth.nhs.uk

  • Sponsor organisation

    Papworth Hospital NHS Foundation Trust - Research and Development Department

  • Eudract number

    2014-001950-41

  • Duration of Study in the UK

    1 years, 5 months, 28 days

  • Research summary

    Obstructive Sleep Apnoea (OSA) is a condition caused by repetitive narrowing/collapse of the upper airway leading to reduction/pauses in airflow during sleep causing intermittent drop of blood oxygen levels.

    This study will investigate the effects of morphine (a drug commonly used for pain relief, including following surgery) on the severity of OSA, measured by Apnoea Hypopnea Index (AHI, number of pauses in breathing per hour of sleep causing significant drops in blood oxygen levels). OSA is common in the adult population and many sufferers are undiagnosed. It is therefore likely patients presenting for surgery (and therefore are prescribed morphine for pain relief following surgery) will have undiagnosed/untreated OSA.

    Potential patients with moderate OSA established on Continuous Positive Airway Pressure (CPAP, a treatment for OSA) will be recruited to the study. Patients will be risk assessed as to their safety to withdraw from CPAP by the study doctor and if safe to do so, will stop CPAP treatment for 6 nights prior to a home sleep study (rPSG, respiratory polygraphy) and the study visit (an overnight inpatient admission) To ensure patient safety, a delegated doctor will be present throughout the whole night and will observe patient's respiration. Recruitment will continue until 26 patients with moderate OSA have succesfully completed the study night (overnight inpatient admission)

    The primary outcome will be change in AHI from baseline to study rPSG. Secondary outcomes include the change in various respiratory variables from baseline to study rPSG.

  • REC name

    East of England - Cambridgeshire and Hertfordshire Research Ethics Committee

  • REC reference

    15/EE/0194

  • Date of REC Opinion

    30 Jun 2015

  • REC opinion

    Further Information Favourable Opinion